A Study to Evaluate the Efficacy of VR for Bipolar Disorder
Launched by SHANGHAI MENTAL HEALTH CENTER · Apr 30, 2024
Trial Information
Current as of August 20, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring the use of virtual reality (VR) as a potential treatment for bipolar disorder, a condition that can cause significant mood swings, including episodes of extreme highs (mania) and lows (depression). The researchers aim to see if VR can help improve the mental health of people diagnosed with bipolar disorder, specifically those currently experiencing a depressive episode. The study is taking place in China and is currently recruiting participants aged 13 and older who meet specific criteria for bipolar disorder.
To be eligible for the study, participants need to have a certain level of depression, as measured by a standard assessment tool. They should be able to understand and communicate effectively to participate in the trial. However, individuals with severe physical health issues, other major mental health disorders, or those who have thoughts of self-harm are not eligible. Participants will receive information about the trial and will need to give their consent to take part. This study could help find new and effective ways to support people living with bipolar disorder.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 13 years or older
- • Meet the diagnostic criteria for bipolar disorder - depressive episode in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5)
- • Able to understand the content of the scale
- • Certain abilities in expressive, reading, and listening
- • Total score of \>17 on the Hamilton Rating Scale for Depression (HAMD-17)
- • Inform consent
- Exclusion Criteria:
- • Poor physical condition unable to participate in the study
- • Currently or previously diagnosed with other major mental disorders according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition（DSM-5）
- • Severe or active physical illnesses that interfere with the study treatment
- • Suicidal or self-harming ideas (defined as a score of \>3 on item 3 of the Hamilton Depression Scale-17 suicide scale)
- • Pregnant or lactating women
- • Participate in other clinical trials within 1 month
- • Epilepsy or severe eye diseases
About Shanghai Mental Health Center
Shanghai Mental Health Center is a leading institution dedicated to advancing mental health research and treatment. As a prominent clinical trial sponsor, the center focuses on innovative therapeutic approaches and evidence-based practices to address a wide range of psychiatric disorders. With a multidisciplinary team of experts and state-of-the-art facilities, the center is committed to enhancing patient care through rigorous clinical trials that contribute to the understanding and management of mental health conditions. Its mission is to foster collaboration among researchers, clinicians, and patients to promote mental well-being and improve outcomes in mental health care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shanghai, Shanghai, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported